REGULATION (EU) NO 536/2014 ON CLINICAL TRIALS AND VULNERABLE GROUPS

被引:0
|
作者
Marino Hernandez, Eduardo L. [1 ]
机构
[1] Univ Barcelona, Fac Farm, Dept Farm & Tecnol Farmaceut, Avda Juan 23 S-N, E-08028 Barcelona, Spain
来源
CUADERNOS DE BIOETICA | 2015年 / 26卷 / 88期
关键词
Clinical Trials; Vulnerable groups; Regulation;
D O I
暂无
中图分类号
B82 [伦理学(道德学)];
学科分类号
摘要
A complete review of the normative established for clinical trials in vulnerable patient is performed. To do that, the basis is the last European norm, that is, the Regulation (EU) No 536/2014 of the European Parliament and of the Council of 16 April 2014 on clinical trials on medicinal products for human use, and repealing Directive 2001/20/EC (Text with EEA relevance). It is checked all related to vulnerable patients from the previous European norm. Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001 and the corresponding transpositions into Spanish law by Royal Decree 223/2004, of February 6, 2004, whereby clinical drug trials and Law 29/2006 of 26 July, on guarantees and regulates use rational use of medicines and health products.
引用
收藏
页码:427 / 430
页数:4
相关论文
共 50 条
  • [42] Where is European Regulation 536/2014 Taking Us?
    Anthony W. Fox
    Pharmaceutical Medicine, 2023, 37 : 343 - 347
  • [43] Where is European Regulation 536/2014 Taking Us?
    Fox, Anthony W.
    PHARMACEUTICAL MEDICINE, 2023, 37 (5) : 343 - 347
  • [44] Implementation of Regulation (EU) No 536/2014 as a Non-commercial Sponsor: An Internal Survey and a Descriptive Analysis of Timelines
    Jelle Stans
    Sara Verbandt
    Stéphanie Kromar
    Angélique Deleersnijder
    Therapeutic Innovation & Regulatory Science, 2023, 57 : 1113 - 1120
  • [45] Implementation of Regulation (EU) No 536/2014 as a Non-commercial Sponsor: An Internal Survey and a Descriptive Analysis of Timelines
    Stans, Jelle
    Verbandt, Sara
    Kromar, Stephanie
    Deleersnijder, Angelique
    THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2023, 57 (05) : 1113 - 1120
  • [46] EU REGULATION OF CLINICAL TRIALS New European Union regulation of clinical trials is not conflicting on deferred consent in emergency situations
    Sheehan, Mark
    BMJ-BRITISH MEDICAL JOURNAL, 2013, 346
  • [47] EU CTR 536/2014: Are We Able to Reap the Benefits by Now?
    Jonnalagadda, Venu Gopal
    ARCHIVES OF IRANIAN MEDICINE, 2024, 27 (06) : 346 - 346
  • [48] Grundzüge des neuen Genehmigungsverfahrens für klinische Arzneimittelprüfungen im Rahmen der Verordnung (EU) Nr. 536/2014 und der Zusammenarbeit zwischen den MitgliedstaatenMain characteristics of the new authorisation procedure for clinical trials with medicinal products according to regulation (EU) no 536/2014 and the cooperation between the member states
    Thomas Sudhop
    Claudia Riedel
    Hartmut Krafft
    Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz, 2023, 66 : 3 - 11
  • [49] Accelerating clinical trials in the EU (ACT EU): transforming the EU clinical trials landscape
    Capone, Giacomo
    Eriksson, Bjoern
    Al, Monique
    van Belkum, Stan
    Broich, Karl
    Lamas, Maria
    Lunzer, Marianne
    Nolan, Lorraine
    Ester, Catriona
    Burgos, Juan Garcia
    Pioppo, Laura
    Zanoletty, Ana
    Arlett, Peter
    NATURE REVIEWS DRUG DISCOVERY, 2024, 23 (11) : 797 - 798
  • [50] First experiences with the implementation of EU Regulation 536/2014 (CTR) from the perspective of non-commercial academic research
    Fuhrmann, Christine
    Reineke, Corinna
    Lang, Britta
    Graehlert, Xina
    BUNDESGESUNDHEITSBLATT-GESUNDHEITSFORSCHUNG-GESUNDHEITSSCHUTZ, 2023, 66 (01) : 38 - 44